Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a sell rating to a hold rating in a research report report published on Wednesday morning.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

Separately, Ladenburg Thalmann Financial Services assumed coverage on Krystal Biotech in a report on Wednesday, October 18th. They set a buy rating and a $23.00 target price on the stock.

Krystal Biotech (KRYS) opened at $10.34 on Wednesday. Krystal Biotech has a 1-year low of $8.03 and a 1-year high of $11.98.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 13th. The company reported ($1.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.52). equities analysts expect that Krystal Biotech will post -1.85 EPS for the current year.

An institutional investor recently bought a new position in Krystal Biotech stock. Highbridge Capital Management LLC bought a new stake in shares of Krystal Biotech Inc (NASDAQ:KRYS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 300,000 shares of the company’s stock, valued at approximately $2,991,000. Highbridge Capital Management LLC owned approximately 3.11% of Krystal Biotech at the end of the most recent reporting period. 30.72% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at

Krystal Biotech Company Profile

Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with Analyst Ratings Network's FREE daily email newsletter.